

Original Article

GSTM1 null genotype is a risk factor for laryngeal cancer

Xuejun Liu, Qijun Fan, Liyan Ni, Fanli Liu, Saiyu Huang, Jinjian Gao, Bobei Chen

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China

Received January 17, 2015; Accepted March 14, 2015; Epub May 15, 2015; Published May 30, 2015

Abstract: It remains unclear whether the Glutathione S-transferase M1 (GSTM1) null genotype influence laryngeal cancer development. This study aimed to investigate the interactions among GSTM1 genotype with regard to laryngeal cancer development. We searched online electronic databases (PubMed, EMBASE and CNKI). The strength of association between the GSTM1 genotype and laryngeal cancer risk was assessed by calculating OR with 95% CI. Finally, a total of 25 case-control studies with 2999 cases and 4942 controls on the association between GSTM1 genotype and laryngeal cancer risk were included in this meta-analysis. The overall result showed that the GSTM1 null genotype was related to an increased risk of laryngeal cancer (OR = 1.34; 95% CI, 1.09-1.63). Subgroup analysis was performed according to ethnicity. The results showed that Asians had an increased risk of laryngeal cancer (OR = 1.90; 95% CI, 1.40-2.57), while no significant increased risk was observed in Caucasians (OR = 1.15; 95% CI, 0.97-1.36). In conclusion, this meta-analysis suggested that GSTM1 null genotype was significantly associated with increased laryngeal cancer risk.

Keywords: Laryngeal cancer, GSTM1, meta-analysis, polymorphism

Introduction

Laryngeal cancer is fourteenth most common cancer in the world and it is the most common cancer in the head and neck [1]. Approximately 13,000 men and women will be diagnosed with laryngeal cancer in the United States in 2012. Tobacco smoking and alcohol drinking are the two major risk factors for the laryngeal carcinoma in the developed countries [2]. However, it was reported that genetic was also play an important role in the laryngeal cancer development.

Oxidative stress has been implicated in the pathogenesis of laryngeal cancer. The glutathione S-transferases (GSTs) are a family of enzymes that have the general function of detoxifying xenobiotics that are capable of generating free radicals, by conjugating them with glutathione. GSTM1 has been extensively studied because its locus is polymorphic with a common null allele that produces a complete lack of the enzyme. The association between the GSTM1 null genotype and laryngeal cancer development is not well established in the cur-

rent literature. Several studies have demonstrated an increased risk of laryngeal cancer risk in subjects with the GSTM1 null genotype, whereas other studies have reported no association between the GSTM1 genotype and laryngeal cancer [3-27]. Therefore, we performed this meta-analysis.

Materials and methods

Search for publications

We searched online electronic databases (PubMed, EMBASE and CNKI) using terms: (Glutathione S-transferase M1 or GSTM1) and (polymorphism or variant or variation) and ("laryngeal cancer"). Additional studies were identified by a hand search from reference of original studies or review articles on this topic. There was no language restriction.

Inclusion and exclusion criteria

The major inclusion criteria were: (1) case-control studies or cohort studies; (2) report the association between GSTM1 genotype and

Table 1. Characteristics of the studies included in this meta-analysis

First author/Year	Ethnicity	No. of case	No. of control	Case		Control	
				Present	Null	Present	Null
Jahnke/1996	Caucasian	269	216	118	151	104	112
Coutelle/1997	Caucasian	18	37	4	14	19	18
Jourenkova/1998	Caucasian	129	172	51	78	82	90
Jaskula-Sztul/1998	Caucasian	171	180	142	29	148	32
Matthias/1998	Caucasian	265	178	114	151	83	95
Morita/1999	Asian	69	164	39	30	81	83
Hong/2000	Asian	82	63	26	56	30	33
Hanna/2001	Caucasian	20	20	16	4	10	10
To-Figueras/2002	Caucasian	204	203	108	96	103	100
Gronau/2003	Caucasian	53	139	38	14	71	68
Risch/2003	Caucasian	245	251	118	127	116	135
Bardakci/2003	Caucasian	36	35	19	17	17	18
Unal/2004	Caucasian	42	47	23	19	57	32
Li/2004	Asian	89	164	39	50	95	69
Gajecka/2005	Caucasian	292	321	152	140	157	164
Gattas/2006	Caucasian	22	102	15	7	31	22
Biselli/2006	Caucasian	22	60	15	7	31	29
Peters/2006	Caucasian	135	753	54	81	349	404
Goloni-Bertollo/2006	Caucasian	16	45	10	6	23	22
Acar/2006	Caucasian	110	197	53	57	123	74
Chatzimichalis/2010	Caucasian	88	102	14	74	14	88
Ruwali/2011	Asian	148	500	70	78	340	160
Lourenco/2011	Caucasian	37	142	23	14	76	66
Tian/2011	Asian	233	102	117	116	80	22
Maurya/2014	Asian	204	749	104	100	515	234

laryngeal cancer; (3) available genotype distribution data in cases and controls or odds ratio (OR) with its 95% confidence intervals (CIs). Exclusion criteria included the following: duplicate publications; case reports; insufficient data; lack of a control group; and abstracts, reviews, talks, and review class documentations.

Data extraction

Data were independently abstracted by two investigators using a standard protocol and data-collection form in accordance to the criteria stated above. Differences among evaluators were resolved by discussion and rereading with the third investigator. The following information was extracted from each included study using a standardized data collection protocol: first author, year of publication, ethnicity of participants, numbers of cases and controls, and genotype number in cases and controls.

Statistical analysis

The strength of association between the GSTM1 genotype and laryngeal cancer risk was assessed by calculating OR with 95% CI. A statistical test for heterogeneity was performed based on the Q statistic. The $P > 0.10$ of the Q-test indicated a lack of heterogeneity among studies. If heterogeneity was observed among the studies, the random-effects model was used to estimate the pooled OR (the DerSimonian and Laird method). Otherwise, the fixed-effects model was adopted (the Mantel-Haenszel method). Stratified analysis was performed by ethnicity. Sensitivity analysis was conducted through sequentially excluded individual studies to assess the stability of the results. Potential publication bias was examined visually in a funnel plot and Egger's test. All statistical tests were performed with the software STATA version 11.0 (Stata Corporation,

GSTM1 and laryngeal cancer




Figure 1. Meta-analysis for the association between GSTM1 null genotype and laryngeal cancer risk.

College station, TX, USA). A P value < 0.05 was considered statistically significant.

Results

Characteristics of studies

Finally, a total of 25 case-control studies with 2999 cases and 4942 controls on the association between GSTM1 genotype and laryngeal cancer risk were included in this meta-analysis. There were 6 studies of Asian population and 19 studies of Caucasian population. The characteristics of studies included in the meta-analysis are presented in **Table 1**.

Data synthesis and meta-analysis

The forest plot of the GSTM1 meta-analysis is shown in **Figure 1**. Heterogeneity was observed in the GSTM1 studies ($P < 0.001$, $I^2 = 75\%$), and therefore, a random-effects model was used. The overall result showed that the GSTM1 null genotype was related to an increased risk of laryngeal cancer (OR = 1.34; 95% CI, 1.09-1.63). Subgroup analyses were performed according to ethnicity. The results showed that Asians had an increased risk of laryngeal cancer (OR = 1.90; 95% CI, 1.40-2.57), while no significant increased risk was observed in

Caucasians (OR = 1.15; 95% CI, 0.97-1.36).

Sensitivity analyses were conducted to assess the influence of each individual study on the pooled OR by removing one study at a time. In the overall meta-analysis, no single study changed the pooled results, which indicates that the results were statistically stable and reliable (**Figure 2**).

Funnel plot and Egger's test were performed to assess the publication bias of the currently available literature. The shapes of the funnel plot appeared symmetrical (**Figure 3**). Egger's test was used to provide statistical evidence for funnel plot symmetry. The p -value of the Egger's test is 0.153, suggesting no evidence of publication bias.

Discussion

There are several studies of the relationship of GSTM1 null genotype and cancers. For example, Gong et al. suggested that GSTM1 null genotype was associated with high risks of prostate cancer [28]. Song et al. indicated that GSTM1 null genotype may slightly increase the risk of hepatocellular carcinoma [29]. Zhang et al. found a significant association between GSTM1 allelic variant and head and neck squamous cell carcinoma [30]. In addition, GSTM1 null genotype also associated with coronary artery disease risk [31] and asthma risk [32].

In this study, we found that GSTM1 null genotype was significantly associated with laryngeal cancer risk. In the subgroup analysis by ethnicity, we found that Asians carrying GSTM1 null genotype had an increased laryngeal cancer risk, while Caucasians did not have an increased laryngeal cancer risk.

The etiology of laryngeal cancer is quite unclear by now. In general, it is a disease caused by both genetic and environmental factors. By now, several genetically polymorphic enzymes like cytochrome P450 1A1 are reported to be related with laryngeal cancer [33]. Besides, several other kinds of environmental factors,




Figure 2. Sensitivity analysis of association between GSTM1 null genotype and laryngeal cancer risk.




Figure 3. Funnel plot of associations between GSTM1 null genotype and laryngeal cancer risk.

such as alcohol intake [34], human papilloma-viruses infection [35] and silica exposure [36] are also reported to be associated with risk of laryngeal cancer.

This study has several limitations that need to be addressed. First, the overall sample size was not large enough. We need to perform more original studies to enhance the reliability and accuracy of our conclusions. In addition, the majority of the subjects included in the studies were Caucasian. To explain the discrepancy in the results caused by the different

races of the subjects, more studies in other ethnic groups are needed. Second, some important information was unavailable and was not reported in the included studies, e.g., pathological subtypes and smoking status,. Therefore, the effects of pathological status, environmental exposure or lifestyle on the association between GSTM1 variant and laryngeal cancer could not be determined in this meta-analysis.

In conclusion, this meta-analysis suggested that GSTM1 null genotype was significantly associated with increased laryngeal cancer risk.

Acknowledgements

This work is supported by the Science and Technology Foundation of Wenzhou City, Zhejiang Province, China (Y2-0140375, URL: <http://www.wzj.gov.cn>).

Disclosure of conflict of interest

None.

Address correspondence to: Bobei Chen, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Tel: 86-0577-88002817; E-mail: chenbobei224@126.com

References

- [1] Villanueva-Reyes A, Strand E, Nazario CM, Irizarry-Ramírez M. Cancer of the larynx in Puerto Rico. *P R Health Sci J* 2008; 27: 196-203.
- [2] Bray I, Brennan P, Boffetta P. Projections of alcohol- and tobacco-related cancer mortality in Central Europe. *Int J Cancer* 2000; 87: 122-8.
- [3] Jahnke V, Matthias C, Fryer A, Strange R. Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. *Am J Surg* 1996; 172: 671-3.

- [4] Coutelle C, Ward PJ, Fleury B. Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. *Hum Genet* 1997; 99: 319-25.
- [5] Jourenkova N, Reinikainen M, Bouchardy C. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. *Cancer Epidemiol Biomarkers Prev* 1998; 7: 19-23.
- [6] Jaskula-Sztul R, Reinikainen M, Husgafvel-Pursiainen K. Glutathione S transferase M1 and T1 genotypes and susceptibility to smoking related larynx cancer. *Biomarkers* 1998; 3: 149-55.
- [7] Matthias C, Bockmühl U, Jahnke V. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. *Pharmacogenetics* 1998; 8: 91-100.
- [8] Morita S, Yano M, Tsujinaka T. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. *Int J Cancer* 1999; 80: 685-8.
- [9] Hong YJ, Lee JK, Lee GH, Hong SI. Influence of glutathione S-transferase M1 and T1 genotypes on larynx cancer risk among Korean smokers. *Clin Chem Lab Med* 2000; 38: 917-9.
- [10] Hanna E, MacLeod S, Vural E, Lang N. Genetic deletions of glutathione-S-transferase as a risk factor in squamous cell carcinoma of the larynx: a preliminary report. *Am J Otolaryngol* 2001; 22: 121-3.
- [11] To-Figueras J, Gené M, Gómez-Catalán J. Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. *Cancer Lett* 2002; 187: 95-101.
- [12] Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? *Otolaryngol Head Neck Surg* 2003; 128: 674-80.
- [13] Risch A, Ramroth H, Raedts V. Laryngeal cancer risk in Caucasians is associated with alcohol and tobacco consumption but not modified by genetic polymorphisms in class I alcohol dehydrogenases ADH1B and ADH1C, and glutathione-S-transferases GSTM1 and GSTT1. *Pharmacogenetics* 2003; 13: 225-30.
- [14] Bardakci F, Canbay E, Degerli N, Coban L, Canbay EI. Relationship of tobacco smoking with GSTM1 gene polymorphism in laryngeal cancer. *J Cell Mol Med* 2003; 7: 307-12.
- [15] Unal M, Tamer L, Ateo NA. Glutathione S-transferase M1, T1, and P1 gene polymorphism in laryngeal squamous cell carcinoma. *Am J Otolaryngol* 2004; 25: 318-22.
- [16] Li L, Lin P, Deng YF, Zhu ZL, Lu HH. Relationship between susceptibility and prognosis of laryngeal cancer and genetic polymorphisms in CYP1A1 and GSTM1. *Zhonghua Er Bi Yan Hou Ke Za Zhi* 2004; 39: 2-7.
- [17] Gajecka M, Rydzanicz M, Jaskula-Sztul R. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. *Mutat Res* 2005; 574: 112-23.
- [18] Gattás GJF, de Carvalho MB, Siraque MS. Genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with head and neck cancer. *Head Neck* 2006; 28: 819-26.
- [19] Biselli JM, De Angelo C, Leal RC, Ruiz MT. GSTT1 and GSTM1 polymorphism in cigarette smokers with head and neck squamous cell carcinoma. *Rev Bras Otorrinolaringol* 2006; 72: 654-8.
- [20] Peters ES, McClean MD, Marsit CJ, Luckett B, Kelsey KT. Glutathione S-transferase polymorphisms and the synergy of alcohol and tobacco in oral, pharyngeal, and laryngeal carcinoma. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 2196-202.
- [21] Goloni-Bertollo EM, Biselli JM, de Lima Corrêa LC. Evaluation of the influence of GSTT1 and GSTM1 null genotypes in head and neck carcinogenesis. *Rev Assoc Med Bras* 2006; 52: 365-8.
- [22] Acar H, Ozturk K, Muslumanoglu MH. Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. *Cancer Genet Cytogenet* 2006; 169: 89-93.
- [23] Chatzimichalis M, Xenellis J, Tzagaroulakis A, Sarof P, Banis K, Gazouli M. GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. *J Laryngol Otol* 2010; 124: 318-23.
- [24] Ruwali M, Singh M, Pant MC, Parmar D. Polymorphism in glutathione S-transferases: susceptibility and treatment outcome for head and neck cancer. *Xenobiotica* 2011; 41: 1122-30.
- [25] Lourenco GJ, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. *Tumour Biol* 2011; 32: 1209-15.
- [26] Tian S, Zhang J, Xiao Q, Zhai J, Yan X, Huang M, Chen F, Li Q, Guan Z. [The association between genetic polymorphisms of GSTM1, GSTT1, GSTP1 and susceptibility to laryngeal carcinoma from the Han people in Guangdong zone]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2011; 25: 204-10.
- [27] Maurya SS, Katiyar T, Dhawan A, Singh S, Jain SK, Pant MC, Parmar D. Gene-environment in-

- teractions in determining differences in genetic susceptibility to cancer in subsites of the head and neck. *Environ Mol Mutagen* 2015; 56: 313-21.
- [28] Gong M, Dong W, Shi Z, Xu Y, Ni W, An R. Genetic polymorphisms of GSTM1, GSTT1, and GSTP1 with prostate cancer risk: a meta-analysis of 57 studies. *PLoS One* 2012; 7: e50587.
 - [29] Song K, Yi J, Shen X, Cai Y. Genetic polymorphisms of glutathione S-transferase genes GSTM1, GSTT1 and risk of hepatocellular carcinoma. *PLoS One* 2012; 7: e48924.
 - [30] Zhang Y, Ni Y, Zhang H, Pan Y, Ma J, Wang L. Association between GSTM1 and GSTT1 allelic variants and head and neck squamous cell carcinoma. *PLoS One* 2012; 7: e47579.
 - [31] Zhang ZX, Zhang Y. Glutathione S-transferase M1 (GSTM1) null genotype and coronary artery disease risk: a meta-analysis. *Int J Clin Exp Med* 2014; 7: 3378-84.
 - [32] Wu CC, Ou CY, Chang JC, Hsu TY, Kuo HC, Liu CA, Wang CL, Chuang CJ, Chuang H, Liang HM, Yang KD. Gender-dependent effect of GSTM1 genotype on childhood asthma associated with prenatal tobacco smoke exposure. *Biomed Res Int* 2014; 2014: 769452.
 - [33] Brockmüller J, Cascorbi I, Henning S, Meisel C, Roots I. Molecular genetics of cancer susceptibility. *Pharmacology* 2000; 61: 212-27.
 - [34] La Vecchia C, Zhang ZF, Altieri A. Alcohol and laryngeal cancer: an update. *Eur J Cancer Prev* 2008; 17: 116-24.
 - [35] Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjänen S. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. *Vaccine* 2013; 31 Suppl 7: H59-70.
 - [36] Chen M, Tse LA. Laryngeal cancer and silica dust exposure: a systematic review and meta-analysis. *Am J Ind Med* 2012; 55: 669-76.